• ABOUT GBR

  • AEROSPACE

  • CHEMICALS

  • MINING

  • PHARMACEUTICALS

INTERVIEWS MORE INTERVIEWS

Katrin Rupalla
CEO, YMMUNOBIO
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200, we have obtained orphan drug status from FDA for the treatment of liver cancer."
United States
Pharma & Life Sciences
Stefan Randl & Paul Spencer
HEAD OF DRUG SUBSTANCE (SR), HEAD OF DRUG DELIVERY & PRODUCT...
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."
United States
Pharma & Life Sciences
Daniel Tellechea
INTERIM CEO, LARGO INC.
"We produce approximately 7% of the global vanadium supply, and on the titanium side, we are expected to produce about two thirds of the Brazilian demand for titanium pigment once the project reaches full capacity."
Mining
Canada
Eric Smith
MANAGING DIRECTOR, CEMENTATION
"Ontario has one of the highest densities of expertise in underground mining out of any of the jurisdictions we work in."
Mining
Canada

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL